Time Sensitive Call to Action - Protect the Rights of Patients and Prescribers
The FDA is funding a study by the National Academies of Science, Engineering, and Medicine (NASEM) on the Clinical Utility of Treating Patients with Compounded “Bioidentical” Hormone Therapy (BHT).
According to the NASEM website, the goal of this FDA funded study is to “examine the clinical utility of treating patients with compounded BHT products. NASEM will provide a report evaluating the available scientific evidence relating to the safety and effectiveness of these products and discussing whether the available evidence supports use of compounded BHT products to treat patients.”
Why is this important to you?
Compounding industry leaders and associations believe that the current information presented to NASEM may be one-sided favoring commercially available HRT products, possibly with predetermined outcomes in mind. The FDA does not understand why compounded forms of these products are prescribed instead of FDA-approved commercial products. Big Pharma cannot meet the needs that customized compounded hormones provide for our patients. It is important that NASEM hears from our providers and patients because the outcome of this report will be the basis for future FDA regulation and could affect the way you practice medicine and restrict access to compounded BHRT for your patients for years to come.
How can you help?
It is extremely important that NASEM hears from providers about the clinical needs and effectiveness of compounded BHRT.
Click here or use the “Take Action” button to provide your valuable feedback to NASEM on the clinical needs for compounded BHRT for you and your patients!
*Comments to NASEM should be sent before September 30th.